Dual effects of growth hormone (GH)-releasing hormone infusion in normal men: somatotroph desensitization and increase in releasable GH
- PMID: 3080467
- DOI: 10.1210/jcem-62-3-591
Dual effects of growth hormone (GH)-releasing hormone infusion in normal men: somatotroph desensitization and increase in releasable GH
Abstract
Continuous infusion of human GH-releasing hormone (GHRH) stimulates GH secretion in normal subjects, but a single supramaximal iv dose of GHRH thereafter elicits a diminished serum GH response compared to that after a saline infusion; the response to the single dose challenge is inversely related to the dose of GHRH previously infused. To determine if this attenuated GH response is a result of depletion of available GH or desensitization of the somatotroph, a 6-h infusion of saline or GHRH (10 ng/kg . min) was administered to 10 normal men, and an iv bolus dose of either GHRH (3.3 micrograms/kg) or regular insulin (0.15 U/kg) was given after 5.5 h of infusion. On both days of GHRH infusion, there was significant stimulation of GH secretion compared to that after saline infusion. The GH response to the supramaximal dose of GHRH was greater after saline infusion than after GHRH infusion, and the GH response to insulin-induced hypoglycemia was significantly greater after GHRH infusion compared with the responses on the other 3 study days. The greatest GH secretion occurred during GHRH infusion followed by insulin administration; therefore, pituitary reserve was not decreased by prior exposure to GHRH. These studies suggest that somatotrophs become partially refractory to GHRH stimulation over time, but remain responsive to an alternate stimulus of GH secretion. We suggest that the hypoglycemia-induced GH response occurs via a reduction in hypothalamic somatostatin secretion, and the attenuated GH response to the supramaximal GHRH dose after GHRH infusion probably represents either partial desensitization or down-regulation of the GHRH receptor.
Similar articles
-
Lack of in vivo somatotroph desensitization or depletion after 14 days of continuous growth hormone (GH)-releasing hormone administration in normal men and a GH-deficient boy.J Clin Endocrinol Metab. 1989 Jan;68(1):22-8. doi: 10.1210/jcem-68-1-22. J Clin Endocrinol Metab. 1989. PMID: 2491864
-
Evidence for a limited growth hormone (GH)-releasing hormone (GHRH)-releasable quantity of GH: effects of 6-hour infusions of GHRH on GH secretion in normal man.J Clin Endocrinol Metab. 1985 Feb;60(2):370-5. doi: 10.1210/jcem-60-2-370. J Clin Endocrinol Metab. 1985. PMID: 3917460
-
Impaired inhibitory effects of somatostatin on growth hormone (GH)-releasing hormone stimulation of GH secretion after short term infusion.J Clin Endocrinol Metab. 1990 Jul;71(1):157-63. doi: 10.1210/jcem-71-1-157. J Clin Endocrinol Metab. 1990. PMID: 1973420
-
Physiological role of somatostatin on growth hormone regulation in humans.Metabolism. 1990 Sep;39(9 Suppl 2):40-2. doi: 10.1016/0026-0495(90)90207-s. Metabolism. 1990. PMID: 1976218 Review.
-
Neuroregulation of growth hormone secretion in domestic animals.Domest Anim Endocrinol. 2001 Feb;20(2):65-87. doi: 10.1016/s0739-7240(01)00084-4. Domest Anim Endocrinol. 2001. PMID: 11311846 Review.
Cited by
-
Suppression of growth hormone (GH) secretion by a selective GH-releasing hormone (GHRH) antagonist. Direct evidence for involvement of endogenous GHRH in the generation of GH pulses.J Clin Invest. 1993 Aug;92(2):695-701. doi: 10.1172/JCI116639. J Clin Invest. 1993. PMID: 8349808 Free PMC article.
-
Rhythm and blues. Neurochemical, neuropharmacological and neuropsychological implications of a hypothesis of circadian rhythm dysfunction in the affective disorders.Psychopharmacology (Berl). 1987;93(3):271-85. doi: 10.1007/BF00187243. Psychopharmacology (Berl). 1987. PMID: 3124158 Review.
-
Long term growth hormone (GH)-releasing hormone and biosynthetic GH therapy in GH-deficient children: comparison of therapeutic effectiveness.J Endocrinol Invest. 1990 Mar;13(3):235-9. doi: 10.1007/BF03349547. J Endocrinol Invest. 1990. PMID: 2195098
-
A prospective study of hypothalamus pituitary function after cranial irradiation with or without radiosensitizing chemotherapy.J Endocrinol Invest. 1994 Sep;17(8):615-23. doi: 10.1007/BF03349671. J Endocrinol Invest. 1994. PMID: 7868799 Clinical Trial.
-
GH responsiveness to repeated GHRH or hexarelin administration in normal adults.J Endocrinol Invest. 1995 Oct;18(9):718-22. doi: 10.1007/BF03349794. J Endocrinol Invest. 1995. PMID: 8719303 Clinical Trial.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources